CytomX TherapeuticsCTMX
About: CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Employees: 122
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
21% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 24
1.63% less ownership
Funds ownership: 66.68% [Q1] → 65.05% (-1.63%) [Q2]
15% less funds holding
Funds holding: 87 [Q1] → 74 (-13) [Q2]
30% less call options, than puts
Call options by funds: $30K | Put options by funds: $43K
37% less capital invested
Capital invested by funds: $98.4M [Q1] → $61.9M (-$36.6M) [Q2]
50% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 26
Research analyst outlook
We haven’t received any recent analyst ratings for CTMX.